Friday, May 24, 2024 8:10:02 PM
manibiotech,
Nope, not cherry picking. The point this uptrend started from was the lifetime double bottom in 2020 and the lowest baseline uptrend started from March to April of that year. I believe history will prove this out and the fact that the price since 2014 has been pretty heavily manipulated. Coincidentally or not that was the year that big pharma research indicated that dendritic cell therapies could improve outcomes for those also utilizing checkpoint inhibitors. Also that year the combo patents for L with checkpoint inhibitors were being brought to the forefront and Mr. Neil Woodford began funding NWBO right about the time another important patent was put in place. Direct was also keeping patients alive longer than expected that year.
So… if you want a possible reason for why the attacks started coming back then I would speculate that some big pharmas didn’t like the upstart NWBO and the respectability of Dr. Linda Liau and others creating a potential threat to the future of THEIR franchises. Those connections have not been established yet which is why I am looking forward to “the rest of the story” as Paul Harvey used to say. Best wishes.
Nope, not cherry picking. The point this uptrend started from was the lifetime double bottom in 2020 and the lowest baseline uptrend started from March to April of that year. I believe history will prove this out and the fact that the price since 2014 has been pretty heavily manipulated. Coincidentally or not that was the year that big pharma research indicated that dendritic cell therapies could improve outcomes for those also utilizing checkpoint inhibitors. Also that year the combo patents for L with checkpoint inhibitors were being brought to the forefront and Mr. Neil Woodford began funding NWBO right about the time another important patent was put in place. Direct was also keeping patients alive longer than expected that year.
So… if you want a possible reason for why the attacks started coming back then I would speculate that some big pharmas didn’t like the upstart NWBO and the respectability of Dr. Linda Liau and others creating a potential threat to the future of THEIR franchises. Those connections have not been established yet which is why I am looking forward to “the rest of the story” as Paul Harvey used to say. Best wishes.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
